Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

55.18USD
2 Jul 2015
Change (% chg)

$-0.26 (-0.47%)
Prev Close
$55.44
Open
$54.97
Day's High
$55.44
Day's Low
$54.87
Volume
179,376
Avg. Vol
279,249
52-wk High
$58.20
52-wk Low
$41.73

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $113,072.20
Shares Outstanding(Mil.): 2,062.56
Dividend: 0.76
Yield (%): 1.38

Financials

  NVO.N Industry Sector
P/E (TTM): 32.54 35.83 39.81
EPS (TTM): 1.70 -- --
ROI: 82.69 17.03 16.23
ROE: 91.03 17.93 17.36
Search Stocks

Novo Nordisk to end German sales of new insulin drug after price row

COPENHAGEN - Denmark's Novo Nordisk, the world's biggest insulin producer, is to stop selling its new long-acting insulin drug Tresiba in Germany following a row over pricing.

01 Jul 2015

Novo Nordisk to end German sales of new insulin drug after price row

COPENHAGEN, July 1 - Denmark's Novo Nordisk , the world's biggest insulin producer, is to stop selling its new long-acting insulin drug Tresiba in Germany following a row over pricing.

01 Jul 2015

BRIEF-Novo Nordisk to stop sale of insulin Tresiba in Germany

** Says that the company has decided to cease distribution of its once-daily basal insulin Tresiba (insulin degludec) in Germany following a negative outcome of price negotiations with the GKV-Spitzenverband, the German national association of statutory health insurance funds.

01 Jul 2015

Cinven agrees to buy majority stake in German Synlab

FRANKFURT - European private equity group Cinven [CINV.UL] has agreed to buy a majority stake in German laboratory operator Synlab from BC Partners [BCPRT.UL], the two buyout groups said on Friday.

26 Jun 2015

UPDATE 1-Cinven agrees to buy majority stake in German Synlab

* Combined businesses to benefit from geography, outsourcing (Adds Cinven, BC Partners comment)

26 Jun 2015

NORDIC STOCKS - Factors to watch on June 8

COPENHAGEN, June 8 - The following stocks may be affected by newspaper reports and other factors on Monday:

08 Jun 2015

BRIEF-Novo Nordisk says 3-year Saxenda treatment reduced diabetes risk

* Treatment with obesity drug Saxenda for three years reduced risk of developing type 2 diabetes compared with placebo

22 May 2015

Novo Nordisk, Baxter clash over hemophilia drug patent

COPENHAGEN - Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement.

20 May 2015

UPDATE 1-Novo Nordisk, Baxter clash over haemophilia drug patent

COPENHAGEN, May 20 - Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement.

20 May 2015

Novo Nordisk rejects Baxter patent claim over Novoeight

COPENHAGEN, May 20 - Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that it had infringed patents on drugs to treat the bleeding disorder haemophilia, the Danish company said on Wednesday.

20 May 2015

Competitors

  Price Chg
Sanofi SA (SASY.PA) €88.18 -0.90
Eli Lilly and Co (LLY.N) $86.14 +1.29

Earnings vs. Estimates

Search Stocks